By Harriet Lefton You don’t need to spend big to pick up premium stock picks… not when you can use the markets’ current …
Cantor analyst William Tanner is out today with a research note on shares of TherapeuticsMD (NYSE:TXMD), after the women’s healthcare company announced that …
Oppenheimer analyst Jay Olson today offers up some tidbits about the upcoming launch of TherapeuticsMD’s (NYSE :TXMD) lead drug Imvexxy. Olson rates TXMD …
TherapeuticsMD (NASDAQ:TXMD) announced this morning that the FDA approved TX-004 for treating symptoms of vulvar and vaginal atrophy (VVA). Once designated as Yuvexxy, …
It’s hard to make money when FDA approvals are priced in, but Cantor analyst remains bullish.
Now that TXMD has disproved the bears with a key victory for Imvexxy, Cantor’s William Tanner angles for another win come October for TX-001.
Will the FDA writing on the wall bode well for three pharmaceutical firms raring for a PDUFA nod this summer? Achaogen (NASDAQ:AKAO) complicated …
TherapeuticsMD (NASDAQ:TXMD) investors have a smile on their faces Wednesday, after the drug maker disclosed that it has entered into negotiations with the FDA regarding …
Oppenheimer’s Jay Olson is liking the setup of TXMD shares more and more amid major commercial potential.
Cantor’s William Tanner explains that while TXMD asset TX-004 has magnetized the Street’s attention in the last half a year, TX-004 boasts a bigger commercial market.